Prostate cancer treatment with Lutetium 177 PSMA therapy Worldwide

LU 177 PSMA treatment aims to kill cancer cells by beta radiation of the isotope Lutetium-177. The radioactive particle binds explicitly to prostate cancer cells regardless of their location. As a result, the drug destroys the primary tumor and distant metastases.

Doctors take blood tests and examine liver and kidney functions before the procedure. But, first, a Ga68-PSMA scan is performed to detect all metastases and determine how well the particular malignant cells accumulate PSMA drug.

The patient is injected intravenously for 20 minutes with the Lutetium medication. After that, he stays in a closed ward protected from radiation for two days because he is a beta radiation source. During the action of the radionuclide, he receives drugs to protect the thyroid gland and kidneys, and copious drinking, if necessary, means to reduce nausea and vomiting. 

The patient can take personal belongings to the ward. They will not become radioactive. The zone of radiation does not exceed 1 millimeter. A day after the therapy, the patient is given a control examination, dosimetry, and kidney scintigraphy.

Doctors achieve reduced prostate cancer metastases up to complete remission as Lu 177 treatment results. However, repeating a couple of sessions at 1-2 months intervals might be required.